Back to Journals » Vascular Health and Risk Management » Volume 8

Absorbable stent: focus on clinical applications and benefits

Authors Gonzalo N, Macaya C

Received 14 December 2011

Accepted for publication 16 January 2012

Published 29 February 2012 Volume 2012:8 Pages 125—132

DOI https://doi.org/10.2147/VHRM.S22551

Review by Single-blind

Peer reviewer comments 3

Nieves Gonzalo, Carlos Macaya

Interventional Cardiology, Cardiovascular Institute. Hospital Clinico San Carlos, Instituto de Investigación Sanitaria del Hospital Clinico San Carlos, Madrid, Spain

Abstract: Coronary stents have improved very significantly the immediate and long-term results of percutaneous coronary interventions. However, once the vessel has healed, the scaffolding function of the stent is no longer needed, and the presence of a permanent metallic prosthesis poses important disadvantages. This has led to the idea of creating new devices that are able to provide mechanical support for a determined period and then disappear from the vessel, allowing its natural healing and avoiding the risks associated with having a permanent metallic cage, such as stent thrombosis. Absorbable stents currently appear as one of the most promising fields in interventional cardiology. The present article will review the available clinical evidence regarding these devices at present and their future perspectives.

Keywords: absorbable stent, bioresorbable stent, absorb, percutaneous coronary intervention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Perindopril for improving cardiovascular events

DiNicolantonio JJ, O’Keefe JH

Vascular Health and Risk Management 2014, 10:539-548

Published Date: 30 August 2014

Percutaneous mechanical thrombectomy for treatment of acute femoropopliteal bypass occlusion

Lichtenberg M, Käunicke M, Hailer B

Vascular Health and Risk Management 2012, 8:283-289

Published Date: 4 May 2012

Mixed dyslipidemias in primary care patients in France

Laforest L, Ambegaonkar BM, Souchet T, Sazonov V, Van Ganse E

Vascular Health and Risk Management 2012, 8:247-254

Published Date: 19 April 2012

Argatroban in the management of heparin-induced thrombocytopenia

Luciano Babuin, Vittorio Pengo

Vascular Health and Risk Management 2010, 6:813-819

Published Date: 1 September 2010

Effectiveness of percutaneous laser revascularization therapy for refractory angina

Michael McGillion, Allison Cook, J Charles Victor, et al

Vascular Health and Risk Management 2010, 6:735-747

Published Date: 26 August 2010

Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection

Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al

Vascular Health and Risk Management 2010, 6:479-494

Published Date: 22 June 2010

Early cardiovascular abnormalities in newly diagnosed obstructive sleep apnea

Jean-Philippe Baguet, Marie Nadra, Gilles Barone-Rochette, et al

Vascular Health and Risk Management 2009, 5:1063-1073

Published Date: 11 December 2009